| abstract |
Provided herein are formulations, process, solid forms, and methods of use relating to 2- (tert-butylamino) -4 - ((1 R, 3R, 4R) -3-hydroxy-4-methylcyclohexylamino) -pyrimidin-5- carboxamid a (Compound I). In another aspect, provided herein are methods for preparing certain compounds, including Compound 1 as described herein, as well as intermediates useful in such methods. In certain aspects, the solid forms of Compound I are useful for inhibiting a kinase in a cell that expresses the kinase, eg, JNK1 or JNK2. In another aspect, the solid forms of Compound I are useful for treating or preventing one or more disorders selected from interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody-mediated rejection, or lupus. |